Steroid solutions more likely to be contaminated

Article

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions.

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions, according to the results of a study published online ahead of print in the British Journal of Ophthalmology.

Danny Kauffmann Jokl, MD and colleagues from Columbia University and New York Medical College, USA conducted a study to assess the frequency of contamination of ophthalmic solutions in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria.

Ten (8%) of the multiple dose solutions were contaminated with bacteria: four (50%) of eight steroid containing anti-inflammatory solutions, two (33%) of six combination antimicrobial and steroid containing anti-inflammatory solutions, two (6%) of 34 solutions for glaucoma treatment and two (4%) of 57 medications for dry eye. No mydriatic, miotic or non-combination antimicrobial solutions were contaminated.

Proteus mirabilis was found in eight (80%) of the 10 contaminated solutions. Thirty percent of the contaminated bottles, upon visual examination, were considered "dirty".

It was discovered that steroid-containing solutions are 5.8 times more likely to be contaminated than steroid-free solutions. The authors believe that the frequent contamination during reuse of certain steroid containing solutions raises the question of whether single-use solutions may offer a safer alternative.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.